Q1 Earnings Forecast for SANA Issued By HC Wainwright

Sana Biotechnology, Inc. (NASDAQ:SANA) – Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Sana Biotechnology in a research note issued on Tuesday, March 18th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.24) per share for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Sana Biotechnology’s current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Sana Biotechnology’s Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.97) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.89) EPS, FY2028 earnings at ($0.77) EPS and FY2029 earnings at ($0.59) EPS.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Monday, March 17th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02.

A number of other equities analysts have also commented on SANA. Jefferies Financial Group initiated coverage on shares of Sana Biotechnology in a research report on Friday, March 14th. They issued a “buy” rating and a $7.00 price objective for the company. TD Cowen raised shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, Citizens Jmp raised shares of Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a report on Tuesday. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Sana Biotechnology currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.80.

Sana Biotechnology Stock Up 2.2 %

SANA stock opened at $2.31 on Thursday. The stock has a 50-day simple moving average of $2.95 and a two-hundred day simple moving average of $3.16. Sana Biotechnology has a twelve month low of $1.52 and a twelve month high of $10.50. The firm has a market capitalization of $519.81 million, a PE ratio of -1.65 and a beta of 1.63.

Hedge Funds Weigh In On Sana Biotechnology

Several institutional investors have recently modified their holdings of the company. Barclays PLC boosted its stake in Sana Biotechnology by 126.6% in the third quarter. Barclays PLC now owns 318,910 shares of the company’s stock worth $1,325,000 after buying an additional 178,179 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Sana Biotechnology in the 4th quarter worth approximately $239,000. FMR LLC boosted its stake in shares of Sana Biotechnology by 16.3% in the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company’s stock valued at $131,494,000 after purchasing an additional 4,438,949 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Sana Biotechnology by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company’s stock valued at $13,175,000 after purchasing an additional 276,055 shares during the last quarter. Finally, Stifel Financial Corp purchased a new position in Sana Biotechnology in the 3rd quarter worth $43,000. 88.23% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the sale, the insider now owns 4,541,511 shares in the company, valued at $29,474,406.39. This trade represents a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 31.10% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.